Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Equity / ADSs
-
Shares outstanding
-
592,878
-
Total 13F shares
-
447,247
-
Share change
-
-28,499
-
Total reported value
-
$2,981,000
-
Price per share
-
$6.67
-
Number of holders
-
11
-
Value change
-
-$159,060
-
Number of sells
-
5
Institutional Holders of Scinai Immunotherapeutics Ltd. - ADSs (BVXV) as of Q2 2018
As of 30 Jun 2018,
Scinai Immunotherapeutics Ltd. - ADSs (BVXV) was held by
11 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
447,247 shares.
The largest 10 holders included
Ibex Investors LLC, BANK HAPOALIM BM, Vantage Investment Advisors, LLC, HighTower Advisors, LLC, Psagot Investment House Ltd., DEUTSCHE BANK AG\, LADENBURG THALMANN FINANCIAL SERVICES INC., UBS Group AG, ROYAL BANK OF CANADA, and WELLS FARGO & COMPANY/MN.
This page lists
11
institutional shareholders reporting positions in this security
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.